Third authorized indication in Europe for Reblozyl

4 March 2023
bristol-myers-squibb_large

The European Commission (EC) has granted full Marketing Authorization for Reblozyl (luspatercept), for treatment in adult patients of anemia associated with non-transfusion-dependent (NTD) beta thalassemia, US pharma major Bristol Myers Squibb (NYSE: BMY) announced on Friday.

Bristol Myers noted that this represents the third approved indication in Europe for Reblozyl, a first-in-class treatment for patients with diseases impacted by anemia.

The decision was based on results from the Phase II BEYOND study, evaluating the efficacy and safety of Reblozyl versus placebo in 145 adults with NTD beta thalassemia.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology